Compugen (CGEN) Short-term Investments (2009 - 2026)
Compugen (CGEN) posted quarterly Short-term Investments of $79.3 million for Q1 2026, up 40.43% year-over-year from $56.5 million in Q1 2025, and up 73.33% on a QoQ basis from $45.8 million in Q4 2025.
Analysis
Compugen (CGEN) Short-term Investments (2009 - 2026) Analysis & Trends
Compugen has reported Short-term Investments for 18 years, with the latest figure at $79.3 million in Q1 2026.
- Short-term Investments for Q1 2026 came in at $79.3 million, up 40.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.3 million (up 40.43% YoY), and the FY2025 annual result was $45.8 million, down 25.47% from the prior year.
- Short-term Investments climbed to $79.3 million in Q1 2026, from $45.8 million in the prior quarter.
- Over five years, Short-term Investments peaked at $88.9 million in Q2 2022 and troughed at $25.1 million in Q4 2023.
- A 5-year average of $58.6 million and a median of $57.5 million in 2025 frame the typical range for Short-term Investments.
- The widest annual swing landed in 2023, when Short-term Investments plunged 65.34%; it then soared 145.07% in 2024.
- A 5-year view of Short-term Investments shows it stood at $72.3 million in 2022, then plunged by 65.34% to $25.1 million in 2023, then soared by 145.07% to $61.4 million in 2024, then declined by 25.47% to $45.8 million in 2025, then soared by 73.33% to $79.3 million in 2026.
- Per Business Quant data, the three most recent Short-term Investments figures were $79.3 million in Q1 2026, $45.8 million in Q4 2025, and $51.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Compugen | 241.50 Mn | 155.89 Mn | -92,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.34 Mn |
| Mar 31, 2026 | 79.32 Mn |
| Dec 31, 2025 | 45.76 Mn |
| Sep 30, 2025 | 51.91 Mn |
| Jun 30, 2025 | 58.54 Mn |
| Mar 31, 2025 | 56.48 Mn |
| Dec 31, 2024 | 61.40 Mn |
| Sep 30, 2024 | 72.35 Mn |
| Jun 30, 2024 | 47.44 Mn |
| Dec 31, 2023 | 25.05 Mn |
| Jun 30, 2023 | 44.30 Mn |
| Dec 31, 2022 | 72.29 Mn |
| Jun 30, 2022 | 88.92 Mn |
| Dec 31, 2021 | 109.25 Mn |
| Jun 30, 2021 | 102.56 Mn |
| Dec 31, 2020 | 116.62 Mn |
| Jun 30, 2020 | 122.96 Mn |
| Dec 31, 2019 | 34.04 Mn |
| Jun 30, 2019 | 30.75 Mn |
| Dec 31, 2018 | 39.21 Mn |